TKI Discontinuation Possible for Some CML Patients
Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2017 Category: Cancer & Oncology Authors: Ehab Atallah, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia & Lymphoma Source Type: news
Cytogenetic Abnormalities Do Not Affect Prognosis in Pediatric CML
Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 22, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news
Kenya: Kenyan Study Shines New Light On Chronic Myeloid Leukaemia
[The Conversation Africa] Chronic myeloid leukaemia is a type of bone marrow cancer that goes on to affect the blood, then other organs and tissues. Previous research has linked it to exposure to high doses of radiation. The Conversation Africa's Health Editor Joy Wanja Muraya asked a team of Kenyan experts to explain their research into what other factors might predispose people to this type of cancer. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 22, 2017 Category: African Health Source Type: news
Insurance Status Influences Chronic Myeloid Leukemia Survival Outcomes
Insurance status at the time of chronic myeloid leukemia diagnosis appears to have an influence on survival outcomes, with the uninsured and those on Medicaid having worse overall survival. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 2, 2017 Category: Cancer & Oncology Authors: Susan Branford, MD Tags: Chronic Myeloid Leukemia Videos Hematologic Malignancies Source Type: news
Ponatinib Extends Survival Over Transplant in Chronic Phase CML
Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation. (Source: CancerNetwork)
Source: CancerNetwork - April 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension. (Source: CancerNetwork)
Source: CancerNetwork - March 29, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
New England Journal of Medicine publishes long-term results of Gleevec ®
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. (Source: World Pharma News)
Source: World Pharma News - March 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Final Results of Landmark Imatinib Study in CML Show Long-Term Benefit
The final, long-term analysis of the landmark IRIS study showed that imatinib ’s efficacy persists over time in patients with CML, and no unacceptable late toxic or cumulative effects were observed. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
Plus, there's no evidence of safety concerns linked to long-term use of the drug, researchers saySource: HealthDay
Related MedlinePlus Page: Chronic Myeloid Leukemia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 8, 2017 Category: Consumer Health News Source Type: news
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
WEDNESDAY, March 8, 2017 -- The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment -- with no signs of additional safety risks, a new study finds.
Gleevec -- known generically as imatinib -- was hailed as a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 8, 2017 Category: Journals (General) Source Type: news
Second-Generation TKIs Can Be Stopped in Many CML Patients
Cessation of second-generation TKIs yielded good treatment-free remission rates in patients with chronic myeloid leukemia who had sustained deep molecular responses. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news
Smoking Worsens Prognosis for Patients With CML
Smoking is linked to mortality and to disease progression among patients with chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies News Source Type: news
CD86 Expression Correlates With Relapse in CML Patients
CML patients who have high expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 on plasmacytoid dendritic cells have a higher risk of relapsing after discontinuing therapy with a tyrosine kinase inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - January 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
Adding Pioglitazone Could Improve Molecular Response in CML Patients
A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5. (Source: CancerNetwork)
Source: CancerNetwork - January 5, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
